MA50356A - Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 - Google Patents
Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1Info
- Publication number
- MA50356A MA50356A MA050356A MA50356A MA50356A MA 50356 A MA50356 A MA 50356A MA 050356 A MA050356 A MA 050356A MA 50356 A MA50356 A MA 50356A MA 50356 A MA50356 A MA 50356A
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic compounds
- compounds intended
- rip1 inhibitors
- kinase
- kinase rip1
- Prior art date
Links
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570892P | 2017-10-11 | 2017-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50356A true MA50356A (fr) | 2021-04-21 |
Family
ID=63840848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050356A MA50356A (fr) | 2017-10-11 | 2018-10-10 | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11673892B2 (enExample) |
| EP (1) | EP3694858B1 (enExample) |
| JP (1) | JP7362600B2 (enExample) |
| KR (1) | KR20200070297A (enExample) |
| CN (1) | CN111201229B (enExample) |
| AU (1) | AU2018348930A1 (enExample) |
| BR (1) | BR112020007067A2 (enExample) |
| CA (1) | CA3078653A1 (enExample) |
| CL (1) | CL2020000944A1 (enExample) |
| CO (1) | CO2020004977A2 (enExample) |
| CR (1) | CR20200151A (enExample) |
| IL (1) | IL273443A (enExample) |
| MA (1) | MA50356A (enExample) |
| MX (1) | MX2020003439A (enExample) |
| PE (1) | PE20211246A1 (enExample) |
| PH (1) | PH12020550253A1 (enExample) |
| RU (1) | RU2020114670A (enExample) |
| SG (1) | SG11202003283TA (enExample) |
| WO (1) | WO2019072942A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| KR102664604B1 (ko) * | 2017-07-14 | 2024-05-14 | 에프. 호프만-라 로슈 아게 | 이환형 케톤 화합물 및 이의 사용 방법 |
| AU2018360270A1 (en) | 2017-10-31 | 2020-03-26 | F. Hoffmann-La Roche Ag | Bicyclic sulfones and sulfoxides and methods of use thereof |
| CN113302193A (zh) * | 2019-01-11 | 2021-08-24 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| CN114591333B (zh) * | 2020-12-04 | 2023-08-01 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的制备方法 |
| WO2023039795A1 (zh) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Rip1激酶抑制剂及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| WO1992004343A1 (fr) * | 1990-09-04 | 1992-03-19 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive de tetrahydrobenzazole |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| AU8071698A (en) | 1997-06-13 | 1998-12-30 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| MXPA03001169A (es) | 2000-08-10 | 2003-06-30 | Pharmacia Italia Spa | Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos. |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| ES2289116T3 (es) | 2001-05-24 | 2008-02-01 | Eli Lilly And Company | Nuevos derivados de pirrol como agentes farmaceuticos. |
| US20030129186A1 (en) | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| CA2791165C (en) | 2002-12-03 | 2015-02-24 | Blanchette Rockefeller Neurosciences Institute | A conjugate comprising cholesterol linked to tetracycline |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| EP2118112B1 (en) | 2007-02-07 | 2015-07-08 | Pfizer Inc. | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
| JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| ES2519565T3 (es) | 2009-07-15 | 2014-11-07 | Janssen Pharmaceuticals Inc. | Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa |
| MX2014000626A (es) | 2011-07-15 | 2014-04-30 | Janssen Pharmaceuticals Inc | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa. |
| MX2014013407A (es) | 2012-05-22 | 2014-11-26 | Hoffmann La Roche | Dipiridilaminas sustituidas y uso de las mismas. |
| BR112015016395A2 (pt) | 2013-01-18 | 2017-07-11 | Hoffmann La Roche | pirazóis 3-substituídos e uso como inibidores de dlk |
| TWI638815B (zh) | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（一） |
| KR20160002850A (ko) | 2013-05-01 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도 |
| MA42164B1 (fr) | 2013-05-01 | 2019-12-31 | Hoffmann La Roche | Composes biheteroaryle et leurs utilisations |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| JP6701225B2 (ja) | 2015-03-09 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 三環式ｄｌｋ阻害剤及びその使用 |
| SG10201913880XA (en) * | 2015-07-02 | 2020-03-30 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
| TWI781920B (zh) | 2016-02-05 | 2022-11-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
-
2018
- 2018-10-10 EP EP18785936.8A patent/EP3694858B1/en active Active
- 2018-10-10 KR KR1020207013188A patent/KR20200070297A/ko not_active Ceased
- 2018-10-10 CN CN201880066460.0A patent/CN111201229B/zh active Active
- 2018-10-10 MX MX2020003439A patent/MX2020003439A/es unknown
- 2018-10-10 MA MA050356A patent/MA50356A/fr unknown
- 2018-10-10 BR BR112020007067-0A patent/BR112020007067A2/pt not_active Application Discontinuation
- 2018-10-10 AU AU2018348930A patent/AU2018348930A1/en not_active Abandoned
- 2018-10-10 SG SG11202003283TA patent/SG11202003283TA/en unknown
- 2018-10-10 PE PE2020000378A patent/PE20211246A1/es unknown
- 2018-10-10 CA CA3078653A patent/CA3078653A1/en active Pending
- 2018-10-10 CR CR20200151A patent/CR20200151A/es unknown
- 2018-10-10 RU RU2020114670A patent/RU2020114670A/ru unknown
- 2018-10-10 WO PCT/EP2018/077656 patent/WO2019072942A1/en not_active Ceased
- 2018-10-10 JP JP2020520532A patent/JP7362600B2/ja active Active
-
2020
- 2020-03-19 IL IL273443A patent/IL273443A/en unknown
- 2020-04-08 CL CL2020000944A patent/CL2020000944A1/es unknown
- 2020-04-09 PH PH12020550253A patent/PH12020550253A1/en unknown
- 2020-04-09 US US16/844,952 patent/US11673892B2/en active Active
- 2020-04-23 CO CONC2020/0004977A patent/CO2020004977A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020114670A (ru) | 2021-11-12 |
| CA3078653A1 (en) | 2019-04-18 |
| CN111201229B (zh) | 2024-08-23 |
| PH12020550253A1 (en) | 2021-02-22 |
| WO2019072942A1 (en) | 2019-04-18 |
| EP3694858B1 (en) | 2023-01-11 |
| KR20200070297A (ko) | 2020-06-17 |
| PE20211246A1 (es) | 2021-07-13 |
| MX2020003439A (es) | 2020-07-29 |
| US20200283446A1 (en) | 2020-09-10 |
| CN111201229A (zh) | 2020-05-26 |
| CL2020000944A1 (es) | 2020-08-21 |
| IL273443A (en) | 2020-05-31 |
| CO2020004977A2 (es) | 2020-05-05 |
| JP7362600B2 (ja) | 2023-10-17 |
| US11673892B2 (en) | 2023-06-13 |
| BR112020007067A2 (pt) | 2020-10-06 |
| CR20200151A (es) | 2020-05-23 |
| EP3694858A1 (en) | 2020-08-19 |
| JP2020536915A (ja) | 2020-12-17 |
| SG11202003283TA (en) | 2020-05-28 |
| AU2018348930A1 (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA53377A (fr) | Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2 | |
| MA50356A (fr) | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA47099A (fr) | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| EP3733673A4 (en) | OXY-FLUORPIPERIDE DERIVATIVES AS KINAS INHIBITOR | |
| MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
| EP3442488A4 (en) | COMPOSITIONS FOR TOPICAL APPLICATION OF COMPOUNDS | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| EP3733671A4 (en) | AMINOFLUOROPERIDINE DERIVATIVES AS KINAS INHIBITOR | |
| MA49956A (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| EP3464275A4 (en) | EGFR INHIBITOR COMPOUNDS | |
| MA45375A (fr) | Composés hétérocycliques utilisés en tant qu'agents antibacteriens | |
| MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac |